Literature DB >> 27795365

Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.

Abby R Kroken1, Faith C Blum1, Madison Zuverink1, Joseph T Barbieri2.   

Abstract

Botulinum neurotoxins (BoNTs) are the most toxic proteins for humans but also are common therapies for neurological diseases. BoNTs are dichain toxins, comprising an N-terminal catalytic domain (LC) disulfide bond linked to a C-terminal heavy chain (HC) which includes a translocation domain (HN) and a receptor binding domain (HC). Recently, the BoNT serotype A (BoNT/A) subtypes A1 and A2 were reported to possess similar potencies but different rates of cellular intoxication and pathology in a mouse model of botulism. The current study measured HCA1 and HCA2 entry into rat primary neurons and cultured Neuro2A cells. We found that there were two sequential steps during the association of BoNT/A with neurons. The initial step was ganglioside dependent, while the subsequent step involved association with synaptic vesicles. HCA1 and HCA2 entered the same population of synaptic vesicles and entered cells at similar rates. The primary difference was that HCA2 had a higher degree of receptor occupancy for cells and neurons than HcA1. Thus, HCA2 and HCA1 share receptors and entry pathway but differ in their affinity for receptor. The initial interaction of HCA1 and HCA2 with neurons may contribute to the unique pathologies of BoNT/A1 and BoNT/A2 in mouse models.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  Clostridium botulinum; TIRF microscopy; botulinum toxin; clostridial neurotoxins; gangliosides; synaptic vesicle protein 2; synaptic vesicles; toxins

Mesh:

Substances:

Year:  2016        PMID: 27795365      PMCID: PMC5203649          DOI: 10.1128/IAI.00795-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors:  T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

Review 3.  Synaptic vesicle recycling: steps and principles.

Authors:  Silvio O Rizzoli
Journal:  EMBO J       Date:  2014-03-03       Impact factor: 11.598

4.  Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E.

Authors:  G Schiavo; O Rossetto; S Catsicas; P Polverino de Laureto; B R DasGupta; F Benfenati; C Montecucco
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

5.  Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport.

Authors:  Laura Restani; Elena Novelli; David Bottari; Paola Leone; Ilaria Barone; Lucia Galli-Resta; Enrica Strettoi; Matteo Caleo
Journal:  Traffic       Date:  2012-05-09       Impact factor: 6.215

6.  Enhancing the protective immune response against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Abby R Kroken; Zhuji Fu; Jung-Ja P Kim; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

7.  Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Authors:  Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

8.  Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.

Authors:  Yasushi Torii; Naotoshi Kiyota; Nakaba Sugimoto; Yuichiro Mori; Yoshitaka Goto; Tetsuhiro Harakawa; Shinji Nakahira; Ryuji Kaji; Shunji Kozaki; Akihiro Ginnaga
Journal:  Toxicon       Date:  2010-10-26       Impact factor: 3.033

9.  Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.

Authors:  Faith C Blum; Amanda Przedpelski; William H Tepp; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

10.  Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.

Authors:  G Schiavo; C C Shone; O Rossetto; F C Alexander; C Montecucco
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

View more
  14 in total

1.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

Review 2.  Protein Toxins That Utilize Gangliosides as Host Receptors.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Prog Mol Biol Transl Sci       Date:  2018-03-17       Impact factor: 3.622

3.  Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C.

Authors:  Roger M Benoit; Martin A Schärer; Mara M Wieser; Xiaodan Li; Daniel Frey; Richard A Kammerer
Journal:  Sci Rep       Date:  2017-03-02       Impact factor: 4.379

Review 4.  The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Authors:  Elena Fonfria; Jacquie Maignel; Stephane Lezmi; Vincent Martin; Andrew Splevins; Saif Shubber; Mikhail Kalinichev; Keith Foster; Philippe Picaut; Johannes Krupp
Journal:  Toxins (Basel)       Date:  2018-05-18       Impact factor: 4.546

Review 5.  Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.

Authors:  Alexander Hawlitschka; Andreas Wree
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

Review 6.  Variability of Botulinum Toxins: Challenges and Opportunities for the Future.

Authors:  Christine Rasetti-Escargueil; Emmanuel Lemichez; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2018-09-13       Impact factor: 4.546

7.  Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.

Authors:  Ya Feng; Wuchao Liu; Lizhen Pan; Cong Jiang; Chengxi Zhang; Yuxuan Lu; Zhiyu Nie; Lingjing Jin
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

Review 8.  Exploiting Botulinum Neurotoxins for the Study of Brain Physiology and Pathology.

Authors:  Matteo Caleo; Laura Restani
Journal:  Toxins (Basel)       Date:  2018-04-25       Impact factor: 4.546

9.  Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats.

Authors:  Veronica Antipova; Andreas Wree; Carsten Holzmann; Teresa Mann; Nicola Palomero-Gallagher; Karl Zilles; Oliver Schmitt; Alexander Hawlitschka
Journal:  Toxins (Basel)       Date:  2018-07-17       Impact factor: 4.546

Review 10.  Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics.

Authors:  Jonathan R Davies; Sai Man Liu; K Ravi Acharya
Journal:  Toxins (Basel)       Date:  2018-10-20       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.